Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Optimal timing of one-shot interventions for epidemic control

Francesco Di Lauro, View ORCID ProfileIstván Z. Kiss, View ORCID ProfileJoel C. Miller
doi: https://doi.org/10.1101/2020.03.02.20030007
Francesco Di Lauro
†Department of Mathematics, School of Mathematical and Physical Sciences, University of Sussex, Falmer, Brighton BN1 9QH, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
István Z. Kiss
†Department of Mathematics, School of Mathematical and Physical Sciences, University of Sussex, Falmer, Brighton BN1 9QH, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for István Z. Kiss
Joel C. Miller
‡Department of Mathematics and Statistics, School of Engineering and Mathematical Sciences, La Trobe University, Bundoora, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Joel C. Miller
  • For correspondence: joel.c.miller.research@gmail.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The interventions and outcomes in the ongoing SARS-CoV-2 pandemic are highly varied. The disease and the interventions both impose costs and harm on society. Some interventions with particularly high costs may only be implemented briefly. The design of optimal policy requires consideration of many intervention scenarios. In this paper we investigate the optimal timing of interventions that are not sustainable for a long period. Specifically, we look at at the impact of a single short-term non-repeated intervention (a “one-shot intervention”) on an epidemic and consider the impact of the intervention’s timing. To minimize the total number infected, the intervention should start close to the peak so that there is minimal rebound once the intervention is stopped. To minimise the peak prevalence, it should start earlier, leading to initial reduction and then having a rebound to the same prevalence as the pre-intervention peak rather than one very large peak. To delay infections as much as possible (as might be appropriate if we expect improved interventions or treatments to be developed), earlier interventions have clear benefit. In populations with distinct subgroups, synchronized interventions are less effective than targeting the interventions in each subcommunity separately.

Author Summary Some interventions which help control a spreading epidemic have significant adverse effects on the population, and cannot be maintained long-term. The optimal timing of such an intervention will depend on the ultimate goal.

  • Interventions to delay the epidemic while new treatments or interventions are developed are best implemented as soon as possible.

  • Interventions to minimize the peak prevalence are best implemented partway through the growth phase allowing immunity to build up so that the eventual rebound is not larger than the initial peak.

  • Interventions to minimize the total number of infections are best implemented late in the growth phase to minimize the amount of rebound.

For a population with subcommunities which would have asynchronous outbreaks, similar results hold. Additionally, we find that it is best to target the intervention asynchronously to each subcommunity rather than synchronously across the population.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the authors' institutions and by The Leverhulme Trust, RPG-2017-370

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Revised and updated, with more discussion about the impact of delaying epidemics.

Data Availability

The model is entirely simulation based. No data has been used.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted October 29, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Optimal timing of one-shot interventions for epidemic control
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Optimal timing of one-shot interventions for epidemic control
Francesco Di Lauro, István Z. Kiss, Joel C. Miller
medRxiv 2020.03.02.20030007; doi: https://doi.org/10.1101/2020.03.02.20030007
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Optimal timing of one-shot interventions for epidemic control
Francesco Di Lauro, István Z. Kiss, Joel C. Miller
medRxiv 2020.03.02.20030007; doi: https://doi.org/10.1101/2020.03.02.20030007

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1103)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (504)
  • Epidemiology (9787)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2323)
  • Geriatric Medicine (223)
  • Health Economics (463)
  • Health Informatics (1566)
  • Health Policy (737)
  • Health Systems and Quality Improvement (606)
  • Hematology (238)
  • HIV/AIDS (507)
  • Infectious Diseases (except HIV/AIDS) (11660)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (240)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2149)
  • Nursing (134)
  • Nutrition (339)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1184)
  • Ophthalmology (366)
  • Orthopedics (129)
  • Otolaryngology (220)
  • Pain Medicine (148)
  • Palliative Medicine (50)
  • Pathology (313)
  • Pediatrics (698)
  • Pharmacology and Therapeutics (302)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2192)
  • Public and Global Health (4676)
  • Radiology and Imaging (782)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (625)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (211)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)